Gh Research Plc · NASDAQ:GHRS

Gh Research — Investor Presentation (December 2021)

29 slides from Gh Research's investor presentation, Dec 6, 2021

  1. Slide 1: Corporate Presentation

    © GH Research Corporate Presentation GH Research PLC (NASDAQ: GHRS) December 2021

  2. Slide 2: Disclaimer Regarding Forward-Looking Statements

    @ GH Research Disclaimer Regarding Forward-Looking Statements This presentation has been prepared by GH Research PLC ("GH Research”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a recommendation, promise or repre

  3. Slide 3: Seeking Ultra-Rapid, Durable Remissions in Depression

    @ GH Research Seeking Ultra-Rapid, Durable Remissions in Depression 2021© GH Research PLC

  4. Slide 4: Pipeline

    @ GH Research Pipeline Stage of Development PROGRAMS INDICATION PRECLINICAL PHASE 1 PHASE 2a PHASE 2b PHASE 3 Milestone Treatment-Resistant Initiate Phase 2b trial Depression (TRD) in TRD GHO01 ee a rr Initiate Phase 2a trial 5-MeO-DMT for inhalation Psychiatric Disorder” > in undisclosed ‘administr

  5. Slide 5: The Problem for Patients with Depression

    @ GH Research The Problem for Patients with Depression Established Therapies are Slow-Acting ... Remission Rates in TRD < 15% (STAR*D study, Remission Rate Over Time, Treatment Step 1 = Citalopram) (STAR*D study, Remission Rates Treatment Steps 1 to 4) = 100% 100% 100% ae ~33% no remission = 5 90% F

  6. Slide 6: Large and Open Depression Market EU and US

    @ GH Research Large and Open Depression Market EU and US First Line MDD ¢ Diagnosed: ~48M ¢ Treated (pharmacotherapy + psychotherapy): ~24M Second Line MDD ¢ Non-response to first line: ~13M Treatment-Resistant Depression (TRD) ¢ Non-response to two prior lines: “9M Patients cycle through ineffectiv

  7. Slide 7: 5-MeO-DMT and GH001

    @ GH Research 5-MeO-DMT and GHOO1 * 5-MeO-DMT (5-Methoxy-N,N-Dimethyltryptamine) | * Naturally-occurring psychoactive substance from tryptamine class Na * Highly potent agonist on 5-HT1A and 5-HT2A receptors | * Psychoactive effects with ultra-rapid onset (within seconds) and short duration (5 to 30

  8. Slide 8: GH001 — Individualized Dosing Regimen (IDR)

    @ GH Research GHO001 — Individualized Dosing Regimen (IDR) Designed to Achieve Ultra-Rapid and Durable Remissions GHO001 Single Dose: poses GHO01 Individualized Dosing Regimen (IDR): a | More Chances for Remission 8 se 1 a 2 ™ ae ee » : Hypothetical 9 = oe 2 : J Remission 8 : Patient 1 bel POPP Ne h

  9. Slide 9: Phase 1 Trial in Healthy Volunteers

    @ GH Research Phase 1 Trial in Healthy Volunteers GH001-HV-101 (Completed)

  10. Slide 10: Design of Phase 1 Trial in Healthy Volunteers

    @ GH Research Design of Phase 1 Trial in Healthy Volunteers (GHO01-HV-101) Part A (Single Dose) Part B (IDR) GHO01 2 mg (n=4) anni eraaieae Primary Endpoint: GHOO1 IDR Primary Endpoint: mg (n=6) * Safety until day 7 HV o; mee * Safety until day 7 acnieve * Peak Experience = * Peak Experience GHO01 1

  11. Slide 11: Part A (Single Dose) and Part B (IDR) — Safety

    @ GH Research Part A (Single Dose) and Part B (IDR) — Safety Study Safety Group review (eae aiSegedose) a0) ee ee + All ADRs mild, except two moderate (*) Abnormal dreams * AILADRs resolved spontaneously ORIEL) a g Clumsiness al * Inhalation well-tolerated Gantiueiemellonece 1 * No noteworthy change

  12. Slide 12: Part A — Peak Experience (PE) Dose-Effects and Inter-Person Variability

    @ GH Research Part A — Peak Experience (PE) Dose-Effects and Inter-Person Variability 100 90 PE 80 Threshold = PE Scale u i-} Average for P4 Pi = pP2 P3 P9 P8 P10 P7 = PS P6 | P13 P11 P14 P12) P15 P18 P17 P16 dose group 2 mg 6 mg 12 mg 18 mg PE, Peak Experience 2021© GH Research PLC

  13. Slide 13: Part B — Peak Experience (PE)

    @ GH Research Part B — Peak Experience (PE) Effect of Intraday Individualized Dosing Regimen 100 90 PE 80 Threshold 70 w 60 o a 50 uu 2 40 30 20 10 0 6 mg 6 mg 12 mg 6mg 12 mg 6 mg 12 mg 18 mg P21 P19 P22 P20 PE, Peak Experience 2021© GH Research PLC

  14. Slide 14: Phase 1/2 Trial in Treatment-Resistant Depression

    @ GH Research Phase 1/2 Trial in Treatment-Resistant Depression GH001-TRD-102 (Completed)

  15. Slide 15: Design of Phase 1/2 Trial in TRD (GH001-TRD-102)

    @ GH Research Design of Phase 1/2 Trial in TRD (GHOO1-TRD-102) Phase 1 (Single Dose) Phase 2 (IDR) GHO001 IDR TRDt GHOO1 12 mg (n=4) Primary Endpoint: TRD* " eee a (n=8) GHOO1 18 me (n=4) * Safety until day 7 (n=8) fant dees * MADRS remission & 3h interval) day 7 (MADRSS10) GHOO1 Administration P@Y

  16. Slide 16: Phase 1 (Single Dose) and Phase 2 (IDR) — Safety

    @ GH Research Phase 1 (Single Dose) and Phase 2 (IDR) — Safety Study Safety Group review * No SAEs * All ADRs mild, except three moderate* + All ADRs resolved spontaneously + Inhalation well-tolerated * No noteworthy changes in vital parameters, except for temporary, non-clinically relevant increase

  17. Slide 17: Phase 1 (Single Dose) — Efficacy (MADRS)

    @ GH Research Phase 1 (Single Dose) — Efficacy (MADRS) MADRS Remission / Response / Improvement Rate Day 7 100% 100% 100% 90% * 2 of 4 (50%) in the 12 mg group and 80% 1 of 4 (25%) in the 18 mg group had a MADRS remission at day 7 70% 60% 50% 40% 30% 25% 20% 10% 0% 50% 50% 50% * 2of 8 patients had a

  18. Slide 18: Phase 2 (IDR) — Efficacy (MADRS)

    @ GH Research Phase 2 (IDR) — Efficacy (MADRS) MADRS Remission / Response / Improvement Rate Day 7 100% 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 87.5% 87.5% * Primary endpoint met: 7 of 8 patients (87.5%) had a MADRS remission at day 7, p<0.0001 * 7 of 8 patients had a PE and 6 of those had a MAD

  19. Slide 19: Phase 2 (IDR) — Efficacy (MADRS Change from Baseline)

    @ GH Research Phase 2 (IDR) — Efficacy (MADRS Change from Baseline) p=0.0018 MADRS Mean Change From Baseline -30 oe eo) 2021© GH Research PLC * Primary endpoint met: 7 of 8 patients (87.5%) had a MADRS remission at day 7, p<0.0001 * 7of 7 remissions from day 1 and 5 of 7 remissions from 2 hours p<0.

  20. Slide 20: MADRS and PE — Observed Improved Outcome in Phase 2 (IDR) vs Phase 1

    @ GH Research MADRS and PE — Observed Improved Outcome in Phase 2 (IDR) vs Phase 1 (Single Dose) 87.5% (7 of 8) 50% (2 of 4) 25% (1 of 4) -24.4 (-76%) -21.0 (-65%) -12.8 (-41%) 87.5% (7 of 8) 50% (2 of 4) 0% (0 of 4) 90.4 (at final dose) 58.2 59.1 PE, Peak Experience; MADRS, Montgomery-Asberg Depres

  21. Slide 21: Phase 1 Clinical Pharmacology Trial in Healthy Volunteers

    @ GH Research Phase 1 Clinical Pharmacology Trial in Healthy Volunteers GHO001-HV-103 (Recently completed, preliminary safety data available)

  22. Slide 22: Design of Phase 1 Clinical Pharmacology Trial in Healthy Volunteers

    @ GH Research Design of Phase 1 Clinical Pharmacology Trial in Healthy Volunteers (GHO01-HV-103) Single-Dose Part IDR Part GHOO1 6 mg (n=8+2 placebo) GHO001 IDR 6, 12, 18 mg to achieve PE (up to 3 doses, 1h interval, n=8) Primary Endpoint: HV HV * Pharmacokinetic (n=30) GHOO1 12 mg (n=8+2 placebo) (

  23. Slide 23: Single Dose and IDR — Safety

    @ GH Research Single Dose and IDR — Safety Preliminary! Safety Review | Singie-dose DR + AILADRs mild [MedDRAPreferredTerm | on mm 1 wed ' Abnormal dreams 1 . All ADRs resolved spontaneously (avec searn(ian® 1 * Inhalation well-tolerated Crying 2 1 5 i izzi 1 * No noteworthy changes in vital paramet

  24. Slide 24: Three-Layer Protection Strategy

    @ GH Research Three-Layer Protection Strategy LAYER 1: REGULATORY EXCLUSIVITY FDA: 5 years (+2.5 years paragraph IV stay) EMA: 10 years (+1 year for new indication) LAYER 2: PATENTS Several patent applications filed: * Novel aerosol compositions of matter of 5-MeO-DMT ¢ Novel manufacturing methods o

  25. Slide 25: Board of Directors & Management

    @ GH Research Board of Directors & Management © &@ 8 & f Florian Sch6nharting Spike Loy Michael Forer Dermot Hanley Duncan Moore MSc JD BA, LLB BSC, MBA MPhil, PhD Chairman of the Board, Co-founder Board Member Board Member Board Member Board Member eye . Sh. ay > Yenmab002ee WECM = BVF Q)vooniate A

  26. Slide 26: Core Development Team

    @ GH Research Core Development Team 2e8as 8 6 Markus Breuer Aaron Cameron Conor Burke Peter Fitzpatrick Viktoria McDonald Aoife Soraghan Dipl. Chem. Dr. rer. nat. BSc, MSc, MBA BSc, PhD, MBA BE, MEM BSc (Hons), ERT BSc, MBS Patent Attorney, Co-founder VP, Technical Development VP, Strategic Innovati

  27. Slide 27: Scientific Advisors

    @ GH Research Scientific Advisors x Madhukar Trivedi Michael Thase Mark Zimmerman Eduard Vieta M.D. M.D. M.D. Prof. Dr. Professor of Psychiatry, Professor of Psychiatry,Perelman School of Medicine Professor of Psychiatry and Human Behavior, Head, Psychiatry Unit, UT Southwestern Medical Center Unive

  28. Slide 28: Anticipated Milestones

    @ GH Research Anticipated Milestones * GHOO1 * Request a pre-IND meeting with the FDA and a Scientific Advice meeting with the EMA in Q1 2022 * Pending outcome of the meetings, initiate randomized, controlled Phase 2b trial in TRD * Request regulatory clearance for two Phase 2a trials in two additio

  29. Slide 29: Seeking Ultra-Rapid, Durable Remissions in Depression

    @ GH Research Seeking Ultra-Rapid, Durable Remissions in Depression 2021© GH Research PLC

GH Research — Investor Presentation (December 2021) on 6ix